GENMAB A/S(GMAB)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

GENMAB A/S (GMAB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GMAB at 77.9/100 on a 32-signal composite quality model, placing it at rank #60 of 2,960 stocks — the top 5% of the AI-ranked universe. GMAB scores in the top quartile across balance sheet strength (99.6), institutional flow (98.1), profitability (96.0). Areas of concern include free cash flow (30.0) and earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (FY 2025), GENMAB A/S reports quarterly revenue of $3.7B, net income of $963.0M. Top institutional holders of GMAB by reported 13-F value include Paradigm Biocapital Advisors, Orbis Allan Gray Ltd, ALLIANCEBERNSTEIN L.P., based on the most recent SEC filings. GMAB trades on the Nasdaq exchange and files with the SEC under CIK 1434265. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GMAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GENMAB A/S directly from SEC EDGAR.